tbuckley/cabot-search huggingface dataset:
American Rheumatism Association: Proceedings of the Annual Meeting, 1951
Authors: R H WICHELHAUSEN, T McP BROWN, L B ROBINSON, W R MERCHANT
Journal: Annals of the Rheumatic Diseases (1951)

If the hypothesis that hypersensitivity phenomena are basic in the pathogenesis of collagenous diseases is accepted, the presence of an antigen, the nature of which remains to be determined, must be postulated.Pleuropneumonia-like organisms have been implicated in rheumatic diseases.Their significance as possible antigens in collagenous disease hypersensitivity states is at present under investigation.The unique properties of human " L " organisms would satisfy the criteria of a persis- tent living antigen, invisible in tissues or invaded cells.These properties also preclude their direct demonstration as aetiological agents.In vitro studies on 28 strains of human " L " organisms reveal marked differences in sensitivity to antibiotics, myochrysine, and nitrogen mustard.Preliminary studies indicate that antibiotics effective in vitro are also effective in vivo.This is manifested by disappearance of demonstrable " L " organisms during administration of aureomycin, chloramphenicol, or terramycin, and by transient exacerbation of clinical symptoms of collagenous diseases.The severity of this reaction parallels the in vitro effectiveness of antibiotics.It can be graded by dosage or route of administration (oral or intravenous).The exacerbation is not due to drug hypersensitivity.It may represent tissue response to antigen release, induced by antibiotics.It can be modified by adminis- tration of agents interfering with hypersensitivity reactions.Discussion.-DR.BROWN: During the past few years many new and hopeful remedies for arthritis have been announced, but after clinical trial and prolonged treatment, each has finally been proven either limited or useless in providing persistent, adequate control of rheumatic diseases in general.The practising physician has encountered patient disappointment and medical uncer- tainty on account of these failures.We have long believed that lasting benefit would be possible only when there was a thorough understanding of the basic mechanism operating in collagen diseases in general.To date there has been no real understanding of the mechanism.To-day we have proposed a new total concept of this mechanism, based on clinical and laboratory studies extending over the past 12 years.We suggested a new clinical approach in June, 1949, and the methods of management making use of it to-day are very encouraging, but we believe 463 copyright.
Gain2: Adjuvant Phase III Trial Comparing an Intensified Dose-Dense Adjuvant Therapy with Enpc Compared with a Dose-Dense, Dose-Adapted Therapy with Dtec Dtdocetaxel in Patients with Primary Breast Cancer and a High Risk of Recurrence
Authors: S. Noeding, H. Forstbauer, G. Wachsmann, A. Ober, A. Schneeweiss, B. Christensen, E. von Abel, E. Grischke, H. Höffkes, P. Klare, Y. Ko, S. Schmatloch, N. Burchardi, S. Loibl, G. von Minckwitz, V. Möbus
Journal: Annals of Oncology (2014)
Ventricular volume of single ventricle with or without palliation and after corrective surgery. Concept of septation procedure.
Authors: Yasuhisa Shimazaki, Yasunaru Kawashima, Hajime Hirose, Susumu Nakano, Hikaru Matsuda, Minoru Ogawa, Shizuo Morimoto
Journal: Circulation (1986)

Ventricular volume measurements of single ventricle were carried out in 20 patients with or without palliation and in 2 after total correction. In the former 20 patients, 6 had a single left ventricle and 14 a single right ventricle, anatomically. Two having total correction were associated with undivided ventricle. In the 20 patients with or without palliation, ventricular end-diastolic volume ranged from 64 to 206 (115 +/- 42) percent of the sum of the normal left and right ventricular volumes. Ejection fraction of single ventricle ranged from 0.40 to 0.64 (0.55 +/- 0.06). There was no significant difference in ventricular volume and ejection fraction between patients with a single left and right ventricle. There was high correlation of ventricular volume with pulmonary to systemic blood flow ratio (r = 0.66, p less than 0.005). This indicates that systemic-to-pulmonary shunt should increase ventricular volume of single ventricle. In two patients after total correction, total ventricular volume was 136 and 166% of the sum of the normal left and right ventricular volumes. Total ejection fraction was 0.55 and 0.33 in the first and second patient, respectively. The prosthetic ventricular septum bulged toward the right ventricle during systole and this shift made the left ventricular volume increase and ejection fraction decrease. Right-to-left ventricular volume ratio at end-diastole was 0.74 and 0.67 in the first and second patient, respectively. These results suggest that 1) larger ventricular volume than the sum of the normal left and right ventricular volumes would be required for septation of single ventricle.(ABSTRACT TRUNCATED AT 250 WORDS)
Tumor Evolution Inferred by Patterns of microRNA Expression through the Course of Disease, Therapy, and Recurrence in Breast Cancer
Authors: Maya Dadiani, Noa Bossel Ben-Moshe, Shani Paluch-Shimon, Gili Perry, Nora Balint, Irina Marin, Anya Pavlovski, Dana Morzaev, Smadar Kahana-Edwin, Ady Yosepovich, Einav Nili Gal-Yam, Raanan Berger, Iris Barshack, Eytan Domany, Bella Kaufman
Journal: Clinical Cancer Research (2016)

Molecular evolution of tumors during progression, therapy, and metastasis is a major clinical challenge and the main reason for resistance to therapy. We hypothesized that microRNAs (miRNAs) that exhibit similar variation of expression through the course of disease in several patients have a significant function in the tumorigenic process.Exploration of evolving disease by profiling 800 miRNA expression from serial samples of individual breast cancer patients at several time points: pretreatment, posttreatment, lymph nodes, and recurrence sites when available (58 unique samples from 19 patients). Using a dynamic approach for analysis, we identified expression modulation patterns and classified varying miRNAs into one of the eight possible temporal expression patterns.The various patterns were found to be associated with different tumorigenic pathways. The dominant pattern identified an miRNA set that significantly differentiated between disease stages, and its pattern in each patient was also associated with response to therapy. These miRNAs were related to tumor proliferation and to the cell-cycle pathway, and their mRNA targets showed anticorrelated expression. Interestingly, the level of these miRNAs was lowest in matched recurrent samples from distant metastasis, indicating a gradual increase in proliferative potential through the course of disease. Finally, the average expression level of these miRNAs in the pretreatment biopsy was significantly different comparing patients experiencing recurrence to recurrence-free patients.Serial tumor sampling combined with analysis of temporal expression patterns enabled to pinpoint significant signatures characterizing breast cancer progression, associated with response to therapy and with risk of recurrence. Clin Cancer Res; 22(14); 3651-62. ©2016 AACR.
Prostate cancer screening, treatment, and outcomes— A population-based study
Authors: G. L. Lu-Yao, P. C. Albertsen, J. L. Stanford, T. A. Stukel, E. S. Walker-Corkery, M. J. Barry
Journal: Journal of Clinical Oncology (2006)

10017 Background: It remains unknown whether more intense prostate cancer screening and treatment reduces prostate cancer mortality. We describe the experiences of two population-based cohorts with 15-years follow-up (1987–2001) to address the following questions: 1) does more intense screening and treatment for prostate cancer lead to lower mortality in community settings, and 2) do older men (age ≥75–79) benefit from more intense prostate cancer screening and treatment. Methods: Population-based cohort study consisting of white male Medicare beneficiaries who resided in the regions covered by the Seattle (N=88,863) and Connecticut (N=114,785) cancer registries. Inclusion criteria are age 65–79 and free of prostate cancer on January 1, 1987. All study subjects were followed through death or the end of 2001. The main outcomes are rates of screening for prostate cancer, treatment with radical prostatectomy, external beam radiotherapy, and prostate cancer specific mortality. Results: Between 1987 and 1990, compared to men in Connecticut, men in the Seattle region were 5.4 times (95% C.I. 4.8 - 6.1) more likely to undergo PSA testing, 2.2 times (95% C.I. 1.8 - 2.7) more likely to under go prostate biopsy, 5.9 times (95% C.I. 5.5 - 6.9) more likely to have radial prostatectomy, and 2.3 times (95% C.I. 2.2 - 2.5) more likely to have external beam radiation. The cumulative risk of radical prostatectomy or external beam radiation reached 9.1% in the Seattle cohort and 5.0% in the Connecticut cohort in 2001. After 15 years of follow-up, prostate cancer mortality rates were similar for subjects in the two study regions (hazard ratio of Seattle to CT: 1.01, 95% C.I. 0.93 - 1.09). For older men (aged 75–79 in 1987), however, the prostate cancer mortality rate was slightly higher in the Seattle than the Connecticut cohort (hazard ratio: 1.16, 95% C.I. 1.02 - 1.32). Conclusion: More intense screening for prostate cancer, surgery or radiation among a cohort of Medicare beneficiaries in the Seattle area compared with their counterparts in Connecticut has not lead to significantly lower mortality from prostate cancer over 15 years of follow-up. No significant financial relationships to disclose.
Malignant Mouse-Liver Tumors Resembling Human Hepatoblastomas
Authors: V. S. Turusov, M. K. Deringer, T. B. Dunn, H. L. Stewart
Journal: JNCI Journal of the National Cancer Institute (1973)

Ninety-nine liver tumors resembling human hepatoblastomas were described. Seventy-five were found in CF-1 male mice, untreated or treated with DDT, the incidence in the untreated mice being about 1%. Twenty-four were found in untreated male and female (YBR×AKR)F1 and (DBA/2×YBR)F1 mice, the incidence being 6%. The neoplasms were in old animals and were almost invariably associated with the ordinary type of hepatoma. Histologically, the vascular component was prominent in many neoplasms and organoid structures composed of undifferentiated cells were arranged around vascular channels or formed rows and rosettes. Osteoid formation was observed in 4 neoplasms. Large hemorrhages, necrosis, fibrosis, and thick capsules were frequent. Of 75 neoplasms in CF-1 mice, 15 metastasized. The similarities and differences between the tumor described and hepatoblastoma in man were discussed.
Selective Induction of Intestinal Tumors in Rats by Methyl(acetoxymethyl)nitrosamine, an Ester of the Presumed Reactive Metabolite of Dimethylnitrosamine2
Authors: Sewa R. Joshi, Jerry M. Rice, Martin L. Wenk, Peter P. Roller, Larry K. Keefer
Journal: JNCI Journal of the National Cancer Institute (1977)

Methyl(acetoxymethyl)nitrosamine (DMN-OAc) was synthesized and tested for toxicity and carcinogenicity in rats to test the hypothesis that alpha-hydroxylation is required for metabolic activation of dimethylnitrosamine (DMN) to a reactive, proximate carcinogen. The acute median lethal doses (LD50) of DMN-OAc and DMN injected ip into 5-week-old male Sprague-Dawley (Charles River (CD) rats were determined to be 0.19 and 0.59 mmole/kg body weight or 25 mg DMN-OAc/kg and 44 mg DMN/kg body weight, respectively. Single ip injections of one-half the LD50 DMN-OAc (13 mg/kg body weight) in 5-week-old rats of both sexes resulted in a high incidence of epithelial tumors of the intestinal tract. Mean survival times for rats with intestinal tumors were 353 days for males and 433 days for females. Tumors were rarely found at other sites. DMN at equivalent toxic (one-half the LD50, 22 mg/kg) and molar (= one-sixth LD50, 7.0 mg/kg) dose levels, yielded (as expected) tumors of kidneys, lungs, and occasionally other organs, but at a much lower incidence. The finding of the potent carcinogenicity of DMN-OAc supported the postulate that alpha-hydroxylation of DMN in vivo generates a proximate carcinogen.
Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ
Authors: Brett Snodgrass
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Recombinant Interferon-beta-1a Plus Ribavirin in the Treatment of Chronic Hepatitis C: A Prospective, Randomised, Comparative Pilot Study
Authors: Hyun Woong Lee, Jie Hyun Kim, Sang Hoon Ahn, Kwang Hyub Han, Ja Kyung Kim, Yong Han Paik, Kwan Sik Lee, Chae Yoon Chon, Young Myoung Moon
Journal: Clinical and Molecular Hepatology (2005)

Background/Objectives: Despite the advancement of treatments for chronic HCV infection, approximately 20% and 50% of patients with HCV genotype 2 or 3 and genotype 1 respectively are unable to achieve sustained virological response (SVR). Interferon (IFN)
Airway lipoxin A4/formyl peptide receptor 2–lipoxin receptor levels in pediatric patients with severe asthma
Authors: Rosalia Gagliardo, Delphine Gras, Stefania La Grutta, Pascal Chanez, Caterina Di Sano, Giusy D. Albano, Isabelle Vachier, Angela M. Montalbano, Giulia Anzalone, Anna Bonanno, Loredana Riccobono, Mark Gjomarkaj, Mirella Profita
Journal: Journal of Allergy and Clinical Immunology (2016)
A placebo-controlled study investigating the dexamethasone-sparing effects of corticorelin acetate in patients with primary or metastatic brain tumors and peritumoral edema
Authors: L. D. Recht, L. Mechtler, S. Phuphanich, A. Hormigo, V. Hines, R. Milsted, P. C. O'Connor, R. P. Ryan, E. T. Wong
Journal: Journal of Clinical Oncology (2009)

2078 Background: The standard therapy for patients with peritumoral edema (PTE) associated with cerebral tumors is long-term dexamethasone (dex), which is associated with significant short- and long-term adverse events (AEs). Corticorelin acetate (CrA) is a synthetic peptide of corticotropin-releasing factor that may have the potential to allow such patients to reduce or stop dex therapy. This study investigated the steroid-sparing effect of CrA in patients with cerebral tumors and PTE. Methods: Patients were randomized to CrA 1.0 mg bid SC (n = 100) or placebo (PLA) SC (n = 100) for 12 weeks. The primary endpoint was the percentage of responders, defined as patients able to reduce their daily dex dose by ≥50% by week 2 and maintain this reduction until week 5, without deterioration in neurologic or performance status. Secondary endpoints included maximum percent dex dose reduction from baseline and proximal myopathy (Kendall Myopathy Scale). Steroid-specific treatment-emergent AEs (TEAEs) were also evaluated. Results: The groups were comparable at baseline. There were more responders in the CrA arm vs the PLA arm (62/100 vs. 47/100; p = 0.03). A maximum dex dose reduction of ≥75% was achieved by 42% of CrA patients vs 22% of PLA patients (p = 0.01). 15% of CrA patients were able to stop dex vs. 6% PLA (p = 0.04). At week 12 vs. baseline, proximal myopathy was improved in the CrA group vs the PLA group for upper limbs (p = 0.06) and lower limbs (p = 0.02). AE profiles in both groups were dominated by dex-associated side effects. The overall AE profiles of the treatment groups were generally similar. Emergent cushingoid signs were seen in 13 PLA vs 2 CrA patients (p = 0.01); 14 PLA patients reported skin/subcutaneous tissue disorders as TEAEs vs. 7 CrA patients (p = 0.07). Conclusions: CrA may benefit patients with symptoms of PTE associated with primary or metastatic cerebral tumors by allowing them to reduce/stop their dex treatment, so reducing the incidence of the steroid-related AEs of myopathy, cushingoid symptoms, and skin disorders. [Table: see text]
Rotation of nilotinib and imatinib for first‐line treatment of chronic phase chronic myeloid leukemia
Authors: Gabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, Antonella Gozzini, Emilio Usala, Angelo M. Carella, Giovanna Rege‐Cambrin, Bruno Martino, Elisabetta Abruzzese, Francesco Albano, Fabio Stagno, Luigia Luciano, Mariella D'Adda, Monica Bocchia, Francesco Cavazzini, Mario Tiribelli, Monia Lunghi, Antonietta Pia Falcone, Caterina Musolino, Luciano Levato, Claudia Venturi, Simona Soverini, Michele Cavo, Giuliana Alimena, Fabrizio Pane, Giovanni Martinelli, Giuseppe Saglio, Gianantonio Rosti, Michele Baccarani
Journal: American Journal of Hematology (2016)

The introduction of second-generation tyrosine-kinase inhibitors (TKIs) has generated a lively debate on the choice of first-line TKI in chronic phase, chronic myeloid leukemia (CML). Despite the TKIs have different efficacy and toxicity profiles, the planned use of two TKIs has never been investigated. We report on a phase 2 study that was designed to evaluate efficacy and safety of a treatment alternating nilotinib and imatinib, in newly diagnosed BCR-ABL1 positive, chronic phase, CML patients. One hundred twenty-three patients were enrolled. Median age was 56 years. The probabilities of achieving a complete cytogenetic response, a major molecular response, and a deep molecular response (MR 4.0) by 2 years were 93%, 87%, and 61%, respectively. The 5-year overall survival and progression-free survival were 89%. Response rates and survival are in the range of those reported with nilotinib alone. Moreover, we observed a relatively low rate of cardiovascular adverse events (5%). These data show that the different efficacy and toxicity profiles of TKIs could be favorably exploited by alternating their use. Am. J. Hematol. 91:617-622, 2016. © 2016 Wiley Periodicals, Inc.
Mustard Gas Injuries to the Eyes
Authors: I Ashkenazi, M Blumenthal, I Avni, M Belkin
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Phase I Open-Label Study to Evaluate the Safety and Tolerability of Medi4736, an Anti-Programmed Cell Death-Ligand 1(Pd-L1) Antibody, in Combination with Tremelimumab in Patients with Advanced Non-Small Cell Lung Cancer (Nsclc)
Authors: S.J. Antonia, S. Goldberg, A. Balmanoukian, R. Narwal, P.B. Robbins, G. D'Angelo, A. Blake-Haskins, J.J. Karakunnel, N. Rizvi
Journal: Annals of Oncology (2014)
Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma
Authors: Yumeng Mao, Nina Eissler, Katarina Le Blanc, John Inge Johnsen, Per Kogner, Rolf Kiessling
Journal: Clinical Cancer Research (2016)

Abstract Purpose: Neuroblastoma is the most common extracranial solid cancer type in childhood, and high-risk patients have poor prognosis despite aggressive multimodal treatment. Neuroblastoma-driven inflammation contributes to the induction of suppressive myeloid cells that hamper efficient antitumor immune responses. Therefore, we sought to enhance antitumor immunity by removing immunosuppression mediated by myeloid cells. Experimental Design: The prognostic values of myeloid cells are demonstrated by analyzing genomic datasets of neuroblastoma patients. The impact of tumor-derived factors on myelopoiesis and local induction of suppressive myeloid cells is dissected by in vitro culture models using freshly isolated human CD34+ hematopoietic stem cells, primary human monocytes, and murine bone marrow cells. To test the therapeutic efficacy of BLZ945 as a monotherapy or in combination with checkpoint inhibitors, we used a transgenic murine model (TH-MYCN) that develops aggressive spontaneous neuroblastoma. Results: We report that infiltrating CSF-1R+ myeloid cells predict poor clinical outcome in patients with neuroblastoma. In vitro, neuroblastoma-derived factors interfere with early development of myeloid cells and enable suppressive functions on human monocytes through M-CSF/CSF-1R interaction. In a transgenic mouse model (TH-MYCN) resembling high-risk human neuroblastoma, antagonizing CSF-1R with a selective inhibitor (BLZ945) modulates the induction of human and murine suppressive myeloid cells and efficiently limit tumor progression. While checkpoint inhibitors are insufficient in controlling tumor growth, combining BLZ945 with PD-1/PD-L1 blocking antibodies results in superior tumor control. Conclusions: Our results demonstrate the essential role of CSF-1R signaling during the induction of suppressive myeloid cells and emphasize its clinical potential as an immunotherapy for human cancers. Clin Cancer Res; 22(15); 3849–59. ©2016 AACR.
Comparison of the Antitumor Activity and Toxicity of 2,4-Diamino-5-(1-adamantyl)-6- methylpyrimidine and 2,4-Diamino-5-(1-adamantyl)-6-ethylpyrimidine 2
Authors: Sigmund F. Zakrzewski, Chandrakant Dave, Fred Rosen
Journal: JNCI Journal of the National Cancer Institute (1978)

The effects of two new compounds, 2,4-diamino-5- (1-adamantyl)-6-methyipyrimidine (DAMP) and 2,4-diamino-5-(1- adamantyl)-6-ethylpyrimidine (DAEP), on the growth of Walker carcinoma 256 were studied. In Sprague-Dawley rats, both compounds inhibited the growth of the Walker tumor, which is naturally resistant to methotrexate. Murphy-Sturm lymphosarcoma, which is extremely sensitive to methotrexate, was not inhibited by DAMP. In contrast, 2,4-dlamino-5-(3′ ,4′-dichlorophenyl)-6- methylpyrimidine (DDMP) inhibited the growth of the Murphy-Sturm and Walker tumors. The toxicity of DAMP and DAEP was characterized by convulsions followed by death; DDMP did not show such toxicity at median lethal doses. DAEP and DAMP reversibly reduced the number of polymorphonuclear leukocytes in the peripheral blood of rats, and DAMP also decreased the lymphocytes and platelets; DDMP markedly reduced all these cellular elements. Consistently, bone marrow was also markedly depressed by DDMP.